Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Sovaldi Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedVentura County Health Care PlanPolicy N/A

    Sovaldi (sofosbuvir) Formulary Exception Coverage

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and formulary exception requests for Sovaldi (sofosbuvir tablets and oral pellets) for chronic or recurrent hepatitis C virus infection in adult and pediatric patients when specified clinical, prior-treatment, specialist-prescriber, combination-therapy, cirrhosis, transplant, and treatment-duration criteria are met.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicySovaldi (sofosbuvir) Formulary Exception Coverage
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNovember 12, 2020
    Next Review DateN/A
    Key ActionSubmit a complete prior authorization request identifying the HCV genotype, patient age, cirrhosis or transplant status, prior therapy, specialist involvement, required combination therapy, and treatment duration.
    SourceLink
    POLICY UPDATE CHANGES

    The policy history documents removal of Mavyret trial requirements from chronic genotype 3 adult criteria.

    The policy history documents removal of Viekira and Viekira XR from the policy.

    The policy history documents revisions requiring prior therapy trials and changing pediatric eligibility to patients at least 3 years of age.

    The policy history documents removal of prior Sovaldi-with-Olysio approval criteria and removal of Olysio from the direct-acting antiviral combination exclusion statement.

    8Approval pathways
    12 weeks

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Most indications
    24 weeksPediatric genotype 3
    ≥3 yearsMinimum pediatric age
    SVR failureRetreatment outcome
    12 monthsLife-expectancy exclusion

    General Coverage Criteria

    General non-qualification criteria

    Patients who meet any of the following do not qualify for Sovaldi.

    Non-qualifying use

    • Incompatible DAA combination: Sovaldi is used with direct-acting antivirals other than Daklinza and ribavirin
    • Limited life expectancy: Life expectancy is less than 12 months due to non-liver-related comorbidities< 12 months
    • Monotherapy: Sovaldi is prescribed as monotherapy
    • Age exclusion: Patient is younger than 3 years< 3 years

    Genotype 1 adults without cirrhosis

    Approve for 12 weeks when all criteria are met.

    • Age: Patient is at least 18 years old≥ 18 years
    • No cirrhosis: Patient does not have compensated Child-Pugh A or decompensated Child-Pugh B or C cirrhosis
    • Prior treatment failure: Completed one course of Epclusa, Harvoni, Zepatier, or Vosevi, brand or generic, and did not achieve SVRSVR not achieved 12 weeks after therapy

      Documentation required

    • Specialist involvement:

    Genotype 1 adults with cirrhosis

    Approve for 12 weeks when all criteria are met.

    • Age: Patient is at least 18 years old≥ 18 years
    • Cirrhosis: Patient has compensated Child-Pugh A or decompensated Child-Pugh B or C cirrhosisChild-Pugh A, B, or C

      Documentation required

    • Prior treatment failure: Completed one course of Epclusa or Harvoni, brand or generic, and did not achieve SVRSVR not achieved 12 weeks after therapy

      Documentation required

    Genotype 2 pediatric patients

    Approve for 12 weeks when all criteria are met.

    • Age: Patient is at least 3 years old≥ 3 years
    • Specialist involvement: Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician
    • Combination therapy: Prescribed in combination with ribavirin
    • Cirrhosis limitation: Patient does not have decompensated Child-Pugh B or C cirrhosisNo Child-Pugh B or C cirrhosis

    Genotype 3 pediatric patients

    Approve for 24 weeks when all criteria are met.

    • Age: Patient is at least 3 years old≥ 3 years
    • Specialist involvement: Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician
    • Combination therapy: Prescribed in combination with ribavirin
    • Cirrhosis limitation: Patient does not have decompensated Child-Pugh B or C cirrhosisNo Child-Pugh B or C cirrhosis

    Genotype 3 adults without cirrhosis

    Approve for 12 weeks when all criteria are met.

    • Age: Patient is at least 18 years old≥ 18 years
    • No cirrhosis: Patient does not have compensated Child-Pugh A or decompensated Child-Pugh B or C cirrhosis
    • Prior treatment failure: Completed one course of Epclusa or Vosevi, brand or generic, and did not achieve SVRSVR not achieved 12 weeks after therapy

      Documentation required

    • Specialist involvement:

    Genotype 3 adults with cirrhosis

    Approve for 12 weeks when all criteria are met.

    • Age: Patient is at least 18 years old≥ 18 years
    • Cirrhosis: Patient has compensated Child-Pugh A or decompensated Child-Pugh B or C cirrhosisChild-Pugh A, B, or C

      Documentation required

    • Prior treatment failure: Completed a course of Epclusa, brand or generic, and did not achieve SVRSVR not achieved 12 weeks after therapy

      Documentation required

    Recurrent HCV after liver transplant

    Approve for 12 weeks when all criteria are met.

    • Age: Patient is at least 18 years old≥ 18 years
    • Post-transplant recurrence: Patient has recurrent HCV after liver transplantation
    • Qualified transplant-center specialist: Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician affiliated with a transplant center
    • Combination therapy: Prescribed in combination with Daklinza and ribavirin

    Continuation therapy

    Approve the remaining duration needed to complete an approved course.

    Continuation for patients already started: Patient has been started on Sovaldi for an indication or condition that meets an approved pathwayRemaining weeks only

    If 3 of 12 weeks have been received, approve 9 additional weeks

    Patients do not qualify for Sovaldi when it is used with direct-acting antivirals other than Daklinza and ribavirin, prescribed as monotherapy, or requested for a patient younger than 3 years. Treatment also does not qualify when life expectancy is < 12 months because of non-liver-related comorbidities.

    For pediatric patients with chronic HCV genotype 2 or 3, coverage requires age ≥ 3 years, combination therapy with ribavirin, and no decompensated cirrhosis. Patients with decompensated Child-Pugh B or C cirrhosis are excluded; coverage is available for patients without cirrhosis or with compensated Child-Pugh A cirrhosis.

    Initial Therapy Pathways

    Genotype 1 adults without cirrhosis — initial therapy

    Approve for 12 weeks when all initial-therapy criteria are met.

    Genotype 1 adults without cirrhosis

    • No cirrhosis: Patient does not have compensated Child-Pugh A or decompensated Child-Pugh B or C cirrhosis
    • Qualifying prior therapy: Completed one course of Epclusa, Harvoni, Zepatier, or Vosevi, brand or generic
    • SVR failure: Did not achieve SVRVirus not undetectable 12 weeks following completion of therapy

      Documentation required

    Continuation of an Approved Course

    Continuation therapy

    Approve only the remaining duration needed to complete the applicable approved course.

    Patients already started on Sovaldi: Patient was started on Sovaldi for an indication or condition listed in the policy and needs the balance of the approved courseRemaining weeks only

    For example, a 12-week course with 3 weeks already received qualifies for 9 additional weeks

    Required Prior Therapy

    StepRequired prior treatmentRequired treatment outcome
    1Completed one course of Epclusa, Harvoni, Zepatier, or Vosevi (brand or generic).Did not achieve sustained viral response (SVR); virus remained undetectable 12 weeks following completion of therapy.
    StepClinical pathwayRequired prior treatmentRequired treatment outcome
    1Genotype 1 with compensated or decompensated cirrhosisCompleted one course of Epclusa or Harvoni (brand or generic).Did not achieve SVR; virus remained undetectable 12 weeks following completion of therapy.
    1Genotype 3 without cirrhosisCompleted one course of Epclusa or Vosevi (brand or generic).Did not achieve SVR; virus remained undetectable 12 weeks following completion of therapy.
    1Genotype 3 with compensated or decompensated cirrhosisCompleted one course of Epclusa (brand or generic).Did not achieve SVR; virus remained undetectable 12 weeks following completion of therapy.

    Approval Duration and Quantity Limits

    Sovaldi quantity limit
    Genotype 1 adult pathways12 weeks per course
    Genotype 2 pediatric pathway12 weeks per course
    Genotype 3 adult and post-liver-transplant pathways12 weeks per course
    Sovaldi quantity limit
    Genotype 3 pediatric pathway24 weeks per course
    Patient ageAt least 3 years
    Required combination therapySovaldi with ribavirin

    Request Submission and Documentation

    Prior Authorization

    Submit a Complete Sovaldi Exception Request

    Submit a complete prior authorization exception request for Sovaldi (sofosbuvir tablets or oral pellets). Include the patient’s HCV genotype, age, cirrhosis status, treatment history and SVR results, prescriber qualifications, requested duration, and all required combination-therapy details.

    • Identify the applicable pathway: genotype 1, genotype 2 or 3 pediatric, genotype 3 adult, or recurrent HCV after liver transplantation.
    • Document the requested regimen, including Daklinza and, where required, ribavirin, and the requested duration: 12 weeks unless the applicable pediatric genotype 3 pathway requires 24 weeks.
    • The medication must be prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician; post-transplant requests require an appropriate prescriber affiliated with a transplant center.
    Step Therapy

    Document Required Prior DAA Therapy

    For adult retreatment pathways, document completion of the required prior direct-acting antiviral regimen. The qualifying prior therapy depends on the patient’s genotype and cirrhosis status.

    Eligibility and Clinical Thresholds

    Minimum age for general qualification
    General minimum ageAt least 3 years
    Pediatric pathwaysGenotype 2 and genotype 3 patients must be at least 3 years old
    Age exclusionPatients younger than 3 years do not qualify
    Life expectancy exclusion
    Exclusion thresholdLife expectancy less than 12 months
    CauseDue to non-liver-related comorbidities
    Coverage effectPatients meeting this condition do not qualify for Sovaldi treatment

    Policy Background

    Sovaldi (sofosbuvir) is used in combination antiviral regimens for chronic or recurrent hepatitis C virus infection. Coverage varies according to HCV genotype, patient age, cirrhosis status, liver-transplant status, prior treatment response, and required companion drugs. The policy distinguishes compensated cirrhosis (Child-Pugh A) from decompensated cirrhosis (Child-Pugh B or C) and generally requires specialist involvement.

    Key Terms

    SVR definition
    AbbreviationSVR
    MeaningSustained viral response
    DefinitionVirus remains undetectable 12 weeks following completion of therapy
    Cirrhosis status definitions
    Compensated cirrhosisChild-Pugh A
    Decompensated cirrhosisChild-Pugh B or C
    Pediatric coverage limitationPediatric genotype 2 and genotype 3 coverage excludes decompensated Child-Pugh B or C cirrhosis
    Policy Summary
    PayerVentura County Health Care Plan
    PolicySovaldi (sofosbuvir) Formulary Exception Coverage
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNovember 12, 2020
    Next Review DateN/A
    Key ActionSubmit a complete prior authorization request identifying the HCV genotype, patient age, cirrhosis or transplant status, prior therapy, specialist involvement, required combination therapy, and treatment duration.
    SourceLink
    On This Page
    General Coverage CriteriaInitial Therapy PathwaysContinuation of an Approved CourseRequired Prior TherapyApproval Duration and Quantity LimitsRequest Submission and DocumentationEligibility and Clinical ThresholdsPolicy BackgroundKey Terms
    Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician
  1. Combination therapy: Prescribed in combination with Daklinza
  2. Specialist involvement: Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician
  3. Required regimen by cirrhosis status

    • Decompensated regimen: Decompensated Child-Pugh B or C cirrhosis and Sovaldi is prescribed with Daklinza and ribavirin
    • Compensated regimen: Compensated Child-Pugh A cirrhosis and Sovaldi is prescribed with Daklinza
  4. Coverage includes no cirrhosis or compensated Child-Pugh A cirrhosis

    Coverage includes no cirrhosis or compensated Child-Pugh A cirrhosis

    Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician
  5. Combination therapy: Prescribed in combination with Daklinza
  6. Specialist involvement: Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician
  7. Combination therapy: Prescribed in combination with Daklinza and ribavirin
  8. Specialist involvement: Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician
  9. Combination therapy: Sovaldi is prescribed in combination with Daklinza
  10. Genotype 1 adults with cirrhosis — initial therapy

    Approve for 12 weeks when all initial-therapy criteria are met.

    Genotype 1 adults with cirrhosis

    • Cirrhosis: Patient has compensated Child-Pugh A or decompensated Child-Pugh B or C cirrhosis

      Documentation required

    • Qualifying prior therapy: Completed one course of Epclusa or Harvoni, brand or generic
    • SVR failure: Did not achieve SVRVirus not undetectable 12 weeks following completion of therapy

      Documentation required

    • Specialist involvement: Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician
    • Required regimen by cirrhosis status

      • Decompensated cirrhosis regimen: Decompensated Child-Pugh B or C cirrhosis with Sovaldi, Daklinza, and ribavirin
      • Compensated cirrhosis regimen: Compensated Child-Pugh A cirrhosis with Sovaldi and Daklinza

    Pediatric genotype 2 and 3 — initial therapy

    Approve when all applicable criteria are met.

    Pediatric genotype 2 or 3

    • Eligible genotype and duration

      • Genotype 2: Chronic HCV genotype 2; approve for 12 weeks12 weeks
      • Genotype 3: Chronic HCV genotype 3; approve for 24 weeks24 weeks
    • Specialist involvement: Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician
    • Combination therapy: Sovaldi is prescribed in combination with ribavirin
    • Cirrhosis limitation: Patient does not have decompensated Child-Pugh B or C cirrhosis

      Coverage includes no cirrhosis or compensated Child-Pugh A cirrhosis

    Genotype 3 adults — initial therapy

    Approve for 12 weeks when all initial-therapy criteria are met.

    Genotype 3 adults

    • Eligible cirrhosis pathway

      • Without cirrhosis: No compensated or decompensated cirrhosis; completed Epclusa or Vosevi and did not achieve SVR; Sovaldi prescribed with Daklinza
      • With cirrhosis: Compensated Child-Pugh A or decompensated Child-Pugh B or C cirrhosis; completed Epclusa and did not achieve SVR; Sovaldi prescribed with Daklinza and ribavirin

        Cirrhosis and prior-treatment documentation required

    • Specialist involvement: Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician

    Recurrent HCV after liver transplant — initial therapy

    Approve for 12 weeks when all initial-therapy criteria are met.

    Recurrent HCV after liver transplant

    • Age: Patient is at least 18 years old≥ 18 years
    • Transplant-center specialist: Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician affiliated with a transplant center
    • Combination therapy: Sovaldi is prescribed in combination with Daklinza and ribavirin
    Sovaldi quantity limit
    Applicable patientsPatients already started on Sovaldi
    Approval amountOnly the remaining duration needed to complete the applicable approved course
    ExampleIf 3 weeks of a 12-week course have been received, approve 9 additional weeks
    • Genotype 1 adults without cirrhosis: one completed course of Epclusa (brand or generic), Harvoni (brand or generic), Zepatier, or Vosevi.
    • Genotype 1 adults with compensated or decompensated cirrhosis: one completed course of Epclusa (brand or generic) or Harvoni (brand or generic).
    • Genotype 3 adults without cirrhosis: one completed course of Epclusa (brand or generic) or Vosevi.
    • Genotype 3 adults with compensated or decompensated cirrhosis: one completed course of Epclusa (brand or generic).
    Documentation Required

    Provide General Supporting Documentation

    Provide general supporting documentation for the exception request. Documentation may include chart notes, prescription claims records, prescription receipts, pharmacy records, laboratory data, and other evidence supporting the requested indication and regimen.

    • Include records sufficient to verify diagnosis, HCV genotype, age, cirrhosis status, prior treatment, treatment response, prescriber qualifications, and requested combination therapy.
    • Submit documentation wherever the criteria identify it as required, including cirrhosis status and failure to achieve SVR.
    Documentation Required

    Document Prior Treatment and SVR Failure

    Document that the patient completed the required prior therapy and did not achieve a sustained viral response. SVR means the virus was undetectable 12 weeks after completion of therapy.

    • Provide treatment records showing completion of the qualifying prior regimen.
    • Provide laboratory results or other documentation showing failure to achieve SVR after the required 12-week post-treatment interval.
    • For genotype 1 or 3 adult retreatment requests, missing completion or SVR documentation may prevent approval.
    Documentation Required

    Document Cirrhosis Status

    When the applicable pathway requires cirrhosis documentation, identify whether the patient has compensated Child-Pugh A or decompensated Child-Pugh B or C cirrhosis and submit supporting records.

    • Genotype 1 and genotype 3 adult cirrhosis pathways require documentation of compensated or decompensated cirrhosis.
    • For genotype 1 cirrhosis, use Daklinza with ribavirin for Child-Pugh B or C disease and Daklinza without ribavirin for Child-Pugh A disease.
    • Pediatric genotype 2 or 3 coverage is available without cirrhosis or with compensated Child-Pugh A cirrhosis, but not with decompensated Child-Pugh B or C cirrhosis.
    Denial Risk

    Avoid General Non-Qualifying Use

    Requests do not qualify when a listed exclusion applies, including prohibited combinations, Sovaldi monotherapy, insufficient life expectancy, or age below 3 years.

    • Do not use Sovaldi in combination with DAAs other than Daklinza and ribavirin.
    • Sovaldi monotherapy is not covered.
    • Patients with life expectancy of less than 12 months due to non-liver-related comorbidities do not qualify.
    • Patients younger than 3 years do not qualify.
    Denial Risk

    Meet Adult Retreatment Prerequisites

    Adult retreatment requests may be denied when the required prior regimen, treatment completion, SVR-failure evidence, specialist involvement, cirrhosis documentation, or combination therapy is absent or does not match the applicable pathway.

    • Verify the patient is at least 18 years old and select the pathway matching genotype and cirrhosis status.
    • Document completion of the specified prior DAA regimen and failure to achieve SVR; the qualifying regimens differ by genotype and cirrhosis status.
    • Use Daklinza alone or with ribavirin exactly as required by the pathway.
    • For recurrent HCV after liver transplantation, document recurrence, genotype 1, 2, or 3, transplant-center-affiliated specialist involvement, and combination therapy with Daklinza and ribavirin.
    Prior Authorization

    Verify Pediatric Eligibility

    Pediatric requests are limited to chronic HCV genotype 2 or 3 patients who are at least 3 years old. The request must include specialist involvement, combination therapy with ribavirin, and documentation that decompensated cirrhosis is absent.

    • Genotype 2 pediatric patients: approve for 12 weeks when criteria are met.
    • Genotype 3 pediatric patients: approve for 24 weeks when criteria are met.
    • Coverage includes patients without cirrhosis or with compensated Child-Pugh A cirrhosis; decompensated Child-Pugh B or C cirrhosis does not qualify.
    • The medication must be prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician and used with ribavirin.
    Adult eligibility age
    Adult age thresholdAt least 18 years
    Covered adult pathwaysGenotype 1, genotype 3, and recurrent HCV after liver transplantation
    Age documentationThe patient must meet the adult age requirement for the applicable pathway
    Pediatric eligibility age
    Pediatric age thresholdAt least 3 years
    Applicable pathwaysChronic HCV genotype 2 or genotype 3 in pediatric patients
    Age exclusionPatients younger than 3 years do not qualify
    Sustained viral response assessment
    SVR assessment timing12 weeks following completion of therapy
    Required resultVirus is undetectable
    Use in retreatment criteriaFailure to achieve this response must be documented for specified adult pathways
    DAA definition
    AbbreviationDAA
    TermDirect-acting antiviral
    Policy usageDirect-acting antivirals are referred to as DAAs